Supplementary Information

Subgenomic and negative sense RNA are not markers of active replication of SARS-CoV-2 in nasopharyngeal swabs

Anthony Chamings ^{1,2*}, Tarka Raj Bhatta ^{1,2}, and Soren Alexandersen^{1,2,3}

¹Geelong Centre for Emerging Infectious Diseases, Geelong, VIC 3220, Australia; ²Deakin University, Geelong, VIC 3220, Australia; ³Barwon Health, University Hospital Geelong, Geelong, VIC 3220 Australia

* Correspondence: anthony.chamings@deakin.edu.au; Tel.: +61-0-352479629

Supplementary Table S1. Ct values obtained from the single target SARS-CoV-2 genomic and subgenomic PCR assays for the swab samples from the 16 SARS-CoV-2 positive individuals, negative individual and pool and from 48hr virus cell culture supernatant.

Individual	Swab	Days since onset	5'UTR	ORF7a	N gene subgenomic		7a Genomic and
	Sample ID	of	Genomic	subgenomic	PCR		Subgenomic
		symptoms/Initial	PCR	PCR			PCR
		swab					
1	GC-28	0* (SARS-CoV-2	ND	ND	NEG	NEG	ND
		NEG)					
2	GC-26	7	25.6	30	27.6	27.4	25.3
3	GC-13	4	29.6	33.3	29.8	30.1	28.6
4	GC-24	14*	35.4	NEG	36.2	NEG	33.6
6	GC-14	0	18.7	23.7	20.2	19.8	17.9
6	GC-23	11	33.7	38.6	34.7	34.6	32.6
6	GC-51	17	39.8	NEG	34.1	35.5	36
7	GC-21	16	35.7	NEG	36.7	NEG	33.7
7	GC-58	47	NEG	NEG	NEG	NEG	NEG
8	GC-25	2	21.5	25.4	21.1	20.9	19.9
11	GC-242	0	27.3	30.3	26.5	26.7	26.1
11	GC-290	11	33.5	36.7	33.5	34.2	31.9
12	GC-251	0	17	21.2	17.6	17.6	16.5
12	GC-288	10	36.7	37.1	34.8	NEG	34.7
13	GC-277	0	20.2	25.1	21.4	21.2	18.9
13	GC-329	19	37	NEG	35.7	NEG	34.6
14	GC-238	0	24.3	29.5	26.7	26.7	22.7
14	GC-291	13	22	24.8	22.8	23	20.4
16	GC-366	14	39	NEG	31.9	38.5	33.7
16	GC-365	17	38.1	NEG	NEG	NEG	34.1
17	GC-316	1	19.5	22.6	19.5	19.6	18.1
18	GC-310	17	21.5	25.9	23.7	23.8	21.7
19	GC-199	1	23	28.1	24.8	24.8	23.1
20	GC-292	10	17.6	20.3	17.5	17.3	17.2
21	GC-243	0	24.7	27.6	23.4	23.7	23.4
SARS-CoV-	Pool of 10	Not specified	ND	ND	NEG	NEG	ND
2 Negative	Neg. swabs						
swab pool							
Cell culture		48hrs post	16.8	20.4	19.5	19.3	ND
48Hr		inoculation					

ND: Test not performed. NEG: SARS-CoV-2 not detected.

*Date of onset of clinical signs not provided. Number of days since the collection of the first nasopharyngeal swabs is shown.

†Sample exhausted

Supplementary Table S2. Ct values obtained from the duplex SARS-CoV-2 genomic and subgenomic PCR assays for the swab samples from the 16 SARS-CoV-2 positive individuals, negative individual and pool and from 48hr virus cell culture supernatant.

Individual	Swab	Days since onset	5'UTR	ORF7a
	Sample ID	of	Genomic	subgenomic
		symptoms/Initial	Duplex	Duplex
		swab	PCR	PCR
1	GC-28	0*	NEG	NEG
2	GC-26	7	23.9	27.5
3	GC-13	4	27.3	30.7
4	GC-24	14*	33.8	NEG
6	GC-14	0	16.8	20.5
6	GC-23	11	31.6	NEG
6	GC-51	17	35.4	NEG
7	GC-21	16	34.5	NEG
7	GC-58	47	NEG	NEG
8	GC-25	2	19	22.4
11	GC-242	0	25.8	28.6
11	GC-290	11	31.9	33.9
12	GC-251	0	15.7	18.9
12	GC-288	10	33.7	NEG
13	GC-277	0	18.3	22.4
13	GC-329	19	34.8	36.6
14	GC-238	0	21.8	27.6
14	GC-291	13	19.9	23.3
16	GC-366	14	34.7	NEG
16	GC-365	17	34.7	NEG
17	GC-316	1	17	20.3
18	GC-310	17	20.5	24.4
19	GC-199	1	20.6	25.6
20	GC-292	10	15.4	18.9
21	GC-243	0	22.7	25.6
SARS-CoV-	Pool of 10	Not specified	ND	ND
2 Negative	Neg. swabs			
swab pool				
Cell culture		48 hrs post	17.3	20
48Hr		inoculation		

ND: Test not performed. NEG: SARS-CoV-2 not detected.

*Date of onset of clinical signs not provided. Number of days since the collection of the first nasopharyngeal swabs is shown.

Supplementary Table S3. Table showing the sequence and position of each of the primers and probes of the SARS-CoV-2 genomic and subgenomic PCR assays.

Set	Primers/ Probes	Sequence (5'->3')	Length	Region	Amplification	
1	SARS-CoV-2-Leader- SA-45-66-F	GATCTCTTGTAGATCTGTTCTC	22	Leader	5'UTR genomic	
	SARS-CoV- 2_TRB_RP4_206_187	GACGAAACCGTAAGCAGCCT	20	5' UTR		
	SARS-CoV-2_TRB_ 5'UTR Sense_148-172 (Cy5)	TGTCGTTGACAGGACACGAGTAACT	25	5' UTR		
	SARS-CoV-2-Leader- SA-45-66-F	GATCTCTTGTAGATCTGTTCTC	22	Leader	ORF-7a sub- genomic	
2	SARS-CoV- 2_TRB_RP1-3-27531- 27512	AAATGGTGAATTGCCCTCGT	20	Orf7a		
	SARS-CoV-2_TRB_ ORF7a Sense_27428- 27455 (VIC)	TCGCTACTTGTGAGCTTTATCACTACCA	28	Orf7a		
3	SARS-CoV- 2_TRB_FP2-27401- 27425	TTATTCTTTTCTTGGCACTGATAAC	25	Orf7a		
	SARS-CoV- 2_TRB_RP1-3-27531- 27512	AAATGGTGAATTGCCCTCGT	20	Orf7a	ORF-7a total	
	SARS-CoV-2_TRB_ ORF7a Sense_27428- 27455 (VIC)	TCGCTACTTGTGAGCTTTATCACTACCA	28	Orf7a		
4	SARS-CoV-2-Leader- SA-45-66-F	GATCTCTTGTAGATCTGTTCTC	22	Leader		
	RP1-SCV2-N-28396- 28378-TRB	CCGACGTTGTTTTGATCGC	19	N gene	N gene sub-	
	SARS-CoV- 2_TRB_N- Probe_Sense_28330- 28355 (FAM)	ACCCTCAGATTCAACTGGCAGTAACC	26	N gene	genomic	

Supplementary Table S4. The names of primers selected from the Ampliseq SARS-CoV-2 Panel amplicons to make the two mini-panels. The 3' end position of each primer is listed in relation to the sequence of SARS-CoV-2 Wuhan-Hu-1 (NC_045512.2). The primer sequence is proprietary of Thermofisher Scientific.

Target	Primer name	Location on SARS- CoV-2 genome (NC_045512.2)
5' UTR Leader (Forward)	R1_1.1363702 F	42
5' UTR – genomic (Reverse)	R1_1.1363702 R	229
S gene (Reverse)	R1_1.22.714732 R	21664
ORF3a (Reverse)	R1_1.26.628976 R	25477
E gene (Reverse)	R1_1.27.887996 R	26307
M gene (Reverse)	R1_1.27.1073732 R	26540
ORF 6 (Reverse)	R1_1.28.162880 R	27095
ORF 7a (Reverse)	R1_1.28.1321347 R	27453
ORF 7b (Reverse)	R1_1.28.99230 R	27701
ORF 8 (Reverse)	R1 1.28.958844 R	27918
N gene (Reverse)	R1_1.29.157415	28336
ORF10 (Reverse)	R2_1.79363 (Reverse	29593*
	complement)	

Mini Panel 1 primers

Mini panel 2 primers

Target	Primer name and location on SARS-CoV-2 genome	Location on SARS- CoV-2 genome (NC_045512.2)
5' UTR Leader (Forward)	R1_1.1.80142 F	52
5' UTR – genomic (Reverse)	R1_1.1363702 R	229
S gene (Reverse)	R1_1.22.714732 R	21664
ORF3a (Reverse)	R1_1.26.628976 R	25477
E gene (Reverse)	R1_1.27.887996 R	26307
M gene (Reverse)	R1_1.27.1073732 R	26540
ORF 6 (Reverse)	R1_1.28.162880 R	27095
ORF 7a (Reverse)	R1_1.28.1321347 R	27453
ORF 7b (Reverse)	R1_1.28.99230 R	27701
ORF 8 (Reverse)	R1 1.28.958844 R	27918
N gene (Reverse)	R1_1.29.157415	28336
ORF10 (Reverse)	R2_1.79363 (Reverse complement)	29593*

*The ORF10 primer was the reverse complement of the original forward primer of this amplicon, and so its 5' end position is provided. We estimate that the primer is 30nt long

Supplementary Figure S1. The Ct values of the four individual PCR assays targeting the genomic 5' UTR, subgenomic ORF7a and N gene, and total ORF7a (detecting genomic and S, ORF3a, E, M, ORF6 and ORF7a subgenomic RNAs) for the naso-oropharyngeal swabs from SARS-CoV-2 positive individuals, the 48 hr cell culture and the SARS-CoV-2 negative pool of swabs. The results are ordered by ascending values of the 5'UTR Ct and show that both the ORF7a and N gene subgenomic, and the ORF7a total PCR Ct's also increase as the UTR Ct increases. Above a Ct of around 30 for the 5'UTR, the detection of subgenomic RNAs becomes less consistent/below levels of detection/quantitation. (n=25 data points from 25 biological samples run once (Subgenomic N run twice)).



Single Target SARS-CoV-2 PCRs

Supplementary Figure S2. Duplex PCR results showing the PCR Ct's for the genomic 5'UTR and the ORF7a subgenomic PCRs. The subgenomic ORF7a PCR was typically 2 to 4 Cts higher than the 5'UTR PCR. Above a 5'UTR Ct of 30, the subgenomic ORF7a assay was not able to consistently detect subgenomic targets. (n=25 data points from 25 biological samples run once)



Duplex SARS-CoV-2 PCRs

Supplementary Figure S3. Scatter plots of the strand specific RNA PCR Ct's and the time between symptom onset and swab collection



Supplementary Figure S4. Relative percentage of reads mapped to each subgenomic RNA using the Ampliseq mini-panel 1, cDNA synthesis with random hexamers and 21 PCR amplification cycles. (n=8 data points from 8 biological samples run once)



sgRNA panel 1 from hexamer cDNA - 21 cycles

Supplementary Figure S5. Relative percentage of reads mapped to each subgenomic RNA using the Ampliseq mini-panel 2, cDNA synthesis with random hexamers and 31 PCR amplification cycles. (n=25 data points from 25 biological samples run once)



10

Supplementary Figure S6. The relative percentage of subgenomic reads from the full SARS-CoV-2 Ampliseq panel.(n=7 data points from 7 biological samples run once)



11

Supplementary Figure S7. Plot of the triplex 5'UTR PCR assay vs the quantity of RNA ($pg/\mu l$) present within a sample as measured by an RNA Pico 6000 chip on an Agilent Bioanalyzer 2100. (n=21 from 21 biological samples run once)



Supplementary Figure S8. The Ct of the triplex SARS-CoV-2 PCRs by the RNA integrity number (RIN) measured by the Bioanalyzer. Samples were divided into three groups, those with no RIN or a RIN<3, those with a RIN between 3 and 6, and those with a high RIN score (>6). Only one nasopharyngeal swab sample had a high RIN. The PCR Ct's showed no relationship with the RIN.

